Sign in
CompletedNo phase

Evaluation of Immunohistochemical Expression of Phosphohistone H3 (PHH3) in Meningioma

Key facts

Who runs it
Sohag University
Where
Egypt1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
50 people enrolled
Started
1 Sept 2026
Ended
22 Oct 2026
Type of study
Observational
Treatments tested
  • Immunohistochemical staining
Record updated
10 November 2026

Who can take part

Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 2 criteriaShow less

Who can take part

  • Histologically confirmed meningioma cases. 2) Cases classified according to WHO CNS5 (2021). 3) Tissue blocks with sufficient material. 4) Specimens with sufficient clinical data; -

Who cannot take part

  • Tissue blocks with insufficient, destroyed or necrotic material. 2) Specimens with insufficient clinical data; -

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Evaluation of Immunohistochemical Expression of Phosphohistone H3 (PHH3) in Meningioma and associate its expression with certain clinical and pathological paramaters as age, sex of the patients, site (right or left and location), size, diagnosis, WHO grade, if there is bone invasion, if there is necrosis and vascular invasion.

The group in the trial

  • Participants

    Fifty (50) cases of meningioma will be performed from archieved formalin-fixed, paraffin-embedded tissue blocks referred to Pathology Department, Sohag University Hospitals.

    Treatment: Immunohistochemical staining

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Record updated
10 November 2026